Mode
Text Size
Log in / Sign up

Deep learning models predict first relapse in 562 adults with idiopathic nephrotic syndrome over 12 months.

Deep learning models predict first relapse in 562 adults with idiopathic nephrotic syndrome over 12 …
Photo by Shubham Dhage / Unsplash
Key Takeaway
Consider deep learning models for relapse risk stratification in idiopathic nephrotic syndrome, pending external validation.

This retrospective cohort study analyzed baseline clinical and laboratory data from 562 adult patients with idiopathic nephrotic syndrome treated between January 2022 and January 2024. The primary outcome was the occurrence of a first relapse within 12 months after the baseline assessment. Three predictive models were compared: a deep learning model, a logistic regression model, and a random forest model.

The deep learning model exhibited the best predictive performance, achieving an area under the curve (AUC) of 0.908 in the training set, 0.900 in the validation set, and 0.883 in the test set. The logistic regression model showed intermediate performance, while the random forest model demonstrated the lowest discriminatory ability. No absolute numbers or p-values were reported for these outcomes.

Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and general tolerability, were not reported for the models or the underlying clinical management. The study did not report specific adverse events associated with the predictive modeling process itself.

A key limitation identified is the need for external validation in larger independent cohorts before clinical implementation. Given the retrospective design and lack of reported p-values or confidence intervals, the certainty of these findings is limited. While deep learning-based models may serve as useful tools for relapse risk stratification, they should not be used for clinical decision-making until validated in broader populations.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background and aimIdiopathic nephrotic syndrome (INS) is a glomerular disorder characterized by proteinuria, hypoalbuminemia, and edema, and relapse remains a major clinical challenge. Early prediction of relapse risk may facilitate individualized treatment and follow-up. This study aimed to develop and compare the performance of logistic regression, random forest, and deep learning models for predicting relapse in adult patients with INS using baseline clinical and laboratory data.MethodsWe conducted a retrospective cohort study of 562 adult patients with idiopathic nephrotic syndrome treated between January 2022 and January 2024. The primary outcome was the first relapse within 12 months after baseline assessment. Baseline demographic characteristics, clinical history, laboratory parameters, and treatment-related variables were collected. The dataset was randomly divided into training (70%), validation (15%), and test (15%) sets. Missing data were imputed, continuous variables were standardized as appropriate, and SMOTE was applied to the training set only to address class imbalance. Three predictive models were developed: logistic regression, random forest, and a deep learning-based neural network. Model performance was evaluated using AUC, accuracy, sensitivity, specificity, and F1-score.ResultsAmong the three models, the deep learning model showed the best predictive performance, with AUCs of 0.908, 0.900, and 0.883 in the training, validation, and test sets, respectively. The logistic regression model showed intermediate performance, whereas random forest showed the lowest discriminatory ability. The most influential predictors of relapse included steroid resistance, nephrotic-range proteinuria at baseline, prior relapse history/frequency, elevated ESR, and immunosuppressant use.ConclusionsDeep learning demonstrated better predictive performance than logistic regression and random forest for predicting 12-month relapse in adult patients with idiopathic nephrotic syndrome. These findings suggest that machine learning-based models, particularly deep learning, may serve as useful tools for relapse risk stratification. External validation in larger independent cohorts is needed before clinical implementation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.